1. Introduction {#sec1-ijerph-17-00656}
===============

Patients treated at intensive care units (ICU) have an increased risk of catching infections. The most common of them is ventilator-associated pneumonia (VAP). According to the new definition announced by the Center of Disease Control and Prevention (CDC), possible and probable VAP is understood as the deterioration of the mechanical ventilation parameters after about two days of stable ventilation, resulting in the increase of positive end expiratory pressure (PEEP) by at least 3 mm H~2~O and an increase in FiO~2~ by at least 20%. Patients have a temperature below 36 °C or above 38 °C and leucocytosis (≤12,000) or leukopenia (≥4000). The definition characterizes a possible VAP if there is a purulent secretion in the bronchial tree and a probable VAP if there is an increase in pathogenic pathogens in microbiological tests \[[@B1-ijerph-17-00656]\].

According to data from 2014, VAP occurs in about 5--15% of patients treated in ICUs \[[@B2-ijerph-17-00656]\] and mortality may be 70% \[[@B1-ijerph-17-00656]\]. In the European Centre for Disease Prevention and Control (ECDC) report, which included data from 2007 \[[@B3-ijerph-17-00656]\], the average incidence was lower than 7%, but the differences between European countries were large and ranged from 3% to 36%. In a subsequent ECDC report in 2014, the average incidence was 6% \[[@B4-ijerph-17-00656]\]. VAP risk factors may be related to the patient's clinical condition, therapy, and staff activities \[[@B5-ijerph-17-00656]\]. The occurrence of complications is determined by many modifiable factors (e.g., body position, sedation, intubation and mechanical ventilation, upper airway instrumentation), as well as non-modifiable factors (e.g., age, duration of stay at the ward, comorbidities) \[[@B5-ijerph-17-00656],[@B6-ijerph-17-00656]\].

Research indicates that the presence of foreign bodies like the endotracheal or gastric tubes are the main cause of VAP because they are most easily colonized by pathogenic agents \[[@B7-ijerph-17-00656],[@B8-ijerph-17-00656],[@B9-ijerph-17-00656]\]. It is very important to learn about other factors---very often unmodified---which predispose the patient to the occurrence of VAP (e.g., comorbidities). This knowledge will allow stricter observation of a patient who is more predisposed to VAP and enables early diagnosis in the case of emerging VAP symptoms.

Undoubtedly, the occurrence of VAP in a patient treated in ICUs significantly worsens the prognosis, increases the costs of treatment, and prolongs the time of hospitalization \[[@B5-ijerph-17-00656],[@B10-ijerph-17-00656],[@B11-ijerph-17-00656]\]. The purpose of the study is a retrospective assessment of risk factors of VAP in patients hospitalized in intensive care units.

2. Materials and Methods {#sec2-ijerph-17-00656}
========================

The study covered 1872 patients hospitalized at the ICU of the University Hospital in Krakow between July 2014 to February 2017. In the analyzed period, there were 2059 patients in the ward. The inclusion criterion included hospitalization in ICUs for a minimum of two full days, therefore, 187 patients who were in the ward for a shorter time were not included in the study. The assessment was carried out on the third, eighth and fifteenth days of hospitalization.

The study used the analysis of medical records, which were the patients' disease histories and TISS (therapeutic intervention scoring system) observation cards. The data was collected using a personal questionnaire.

The analysis criterion included gender, age, diagnosis, and co-morbidities. The analysis also included data on airway instrumentation in patients, the type and frequency of evacuated secretion, the presence of the oropharyngeal tube and the gastric tube, information on the length of intubation, duration of mechanical ventilation, and VAP diagnosis.

VAP was diagnosed following the definitions created by the CDC as well as the ECDC, taking into account microbiological diagnoses \[[@B12-ijerph-17-00656],[@B13-ijerph-17-00656],[@B14-ijerph-17-00656]\]. Permission to conduct the study was obtained from the Director of the University Hospital in Krakow, and all analyses of medical documentation were performed according to ethical standards and the principles of the Declaration of Helsinki.

The results were presented by qualitative and quantitative analysis (%). The qualitative variables were compared using the *Chi*^2^ test. The *p* \< 0.05 value was assumed to be statistically significant.

3. Results {#sec3-ijerph-17-00656}
==========

In the analyzed group, men prevailed *n* = 1094 (58%) in relation to women *n* = 778 (42%). The length of stay (LOS) in ICUs varied between 3 to 69 days. The average LOS of the respondents at the ICU was 3346 man-days. The average duration of the women's stay was shorter than that of the men's. The most common co-morbidities occurring among the studied patients were arterial hypertension *n* = 1216 (65%), diabetes *n* = 709 (38%), obesity *n* = 290 (15%), atherosclerosis *n* = 211 (11%), alcoholism *n* = 201 (11%), thromboembolism *n* = 161 (9%), and COPD *n* = 74 (4%). The characteristics of the studied group are presented in [Figure 1](#ijerph-17-00656-f001){ref-type="fig"} and [Figure 2](#ijerph-17-00656-f002){ref-type="fig"}.

Data analysis showed a statistical significance between the length of hospitalization and the occurrence of VAP. The most common diagnosis was in patients staying in the ward for over 15 days (17%). In the group of patients treated within 3--7 days, only 1% were diagnosed with VAP.

In the group of analyzed comorbidities, highly statistically significant associations were found between the occurrence of such diseases as obesity, alcoholism, diabetes, and COPD and VAP ([Table 1](#ijerph-17-00656-t001){ref-type="table"}).

Also, the reasons for admission to the ICU have proven to be important in light of the possibility of VAP. The analysis showed a statistical significance between the occurrence of VAP and multi-organ injury (*p* = 0.000), fractures (*p* = 0.000), and hemorrhagic/hemorrhagic shock (*p* = 0.000), as direct causes of admitting patients to the ICU ([Table 2](#ijerph-17-00656-t002){ref-type="table"}).

Ventilator-associated pneumonia occurred in the majority of patients hospitalized due to the above-mentioned factors.

There was no statistically significant correlation between the presence of the oropharyngeal tube in intubated patients and the occurrence of VAP. The complication related to 1% of subjects ([Table 3](#ijerph-17-00656-t003){ref-type="table"}).

An extremely important issue was the type of airway instrumentation, and its relationship with the occurrence of VAP turned out to be statistically significant (*p* = 0.047; [Table 4](#ijerph-17-00656-t004){ref-type="table"}).

4. Discussion {#sec4-ijerph-17-00656}
=============

Based on the results of our personal research, it has been shown that many factors influence the occurrence of pneumonia associated with mechanical ventilation in ICUs. These are mainly due to mechanical ventilation, airway instrumentation, and length of hospitalization. Similar results were provided by Bobik and Siemiątkowski \[[@B15-ijerph-17-00656]\], who showed that VAP occurs in 8--28% of mechanically ventilated patients. Furthermore, in patients treated at the ICU, this percentage increases to 27--30%, increasing the risk of complications by 3 to 10 times. The mentioned authors also showed that the use of mechanical ventilation and intubation causes a 21-fold increase in the incidence of VAP, and the risk increases steadily with each day of mechanical ventilation.

In our own study, it was shown that the length of hospitalization and the time of using mechanical ventilation had a significant influence on the occurrence of VAP. Similar results were presented by Karpel \[[@B16-ijerph-17-00656]\], which shows that the increased risk of VAP is dependent on the length of mechanical ventilation, and Szeter \[[@B17-ijerph-17-00656]\], indicating an increased risk of VAP by 1--3% for each day of mechanical ventilation. Also, the results of the research presented by Kubisz \[[@B18-ijerph-17-00656]\] are similar to the results of their own reports. The author emphasizes that when ICU hospitalization is prolonged beyond 72 h, the risk of pneumonia increases 12-fold.

In Rosenthal et al. \[[@B19-ijerph-17-00656]\], a report from 50 countries on VAP incidences ranged from 0.9 and 13.1 per 1000 ventilator-days. Ventilator-associated pneumonia density in the American CDC NHSN program from 2012 was, on average, 0.9 per 1000 ventilator-days \[[@B20-ijerph-17-00656]\]. In European countries, in a study published in 2012, the mean density of VAP was 8 in 1000 with intubation \[[@B1-ijerph-17-00656]\]. In another earlier study of Rosenthal et al., a report from 55 ICUs from 46 hospitals showed VAP incidences ranged from 10.0 to 52.7 per 1000 ventilator-days (the countries of southern America, Turkey, India) \[[@B21-ijerph-17-00656]\].

Noteworthy are the results regarding the relationship between co-morbidities and the occurrence of VAP. In the VAP study, this was found more frequently in patients with co-existing COPD, alcoholism, diabetes, and obesity. In the study by Rajnan et al. \[[@B22-ijerph-17-00656]\], VAP occurred in 57% of patients with diagnosed COPD. The results presented by Blot showed a relationship between the occurrence of VAP and diabetes \[[@B23-ijerph-17-00656]\].

In our study, there was a correlation between the reason for patient ICU admission and the occurrence of VAP. Patients with multi-organ trauma, hemorrhage/hemorrhagic shock and fractures more often suffered from VAP. The results of studies by Rajnan N. et al. \[[@B22-ijerph-17-00656]\] have also shown that the risk of developing VAP in patients with trauma was 76%.

There is a relationship between the type of airway instrumentation and the incidence of VAP. Patients with an inserted endotracheal tube are more likely to develop VAP than patients with a tracheotomy. In our research, pneumonia was more common in intubated patients (6%) than those with a tracheotomy (less than 0.5%). On the fifteenth day of hospitalization, VAP was diagnosed in the majority of intubated patients. Similar results were obtained in the research studies by Karaoglan et al. \[[@B24-ijerph-17-00656]\] in which the risk of VAP increased 7-fold among VAP patients, and 3-fold among patients with tracheotomies. Pirożyński et al. \[[@B25-ijerph-17-00656]\] showed similar relationships in their studies. He stressed that the patient's intubation is one of the highest risk factors for VAP. According to the authors, the chances of the occurrence of pneumonia in the case of intubated patients increases by as much as 6 to 21 times.

In our study, there was no correlation between the presence of the oropharyngeal tube and VAP risk. In 1% of the patients intubated and in the gyroconeal section, VAP was diagnosed, while 24% were hospitalized with a laryngeal tube but did not have VAP.

The lack of association between the occurrence of pneumonia in patients treated in the ICU and the presence of laryngeal tubes may be associated with nurses administering oral cleaning in accordance with established procedures \[[@B23-ijerph-17-00656],[@B24-ijerph-17-00656],[@B25-ijerph-17-00656]\].

5. Conclusions {#sec5-ijerph-17-00656}
==============

There is a need for further research into the risk factors of non-modifiable VAP, such as comorbidities, and the reasons for admission to ICUs in order to allow closer monitoring of these patients for VAP. Patients with acute respiratory failure, multi-organ trauma, fractures, or hemorrhage/hemorrhagic shock are groups with a predisposition to the occurrence of VAP.Particular attention should be paid to patients with comorbid COPD, obesity, diabetes, or alcoholism as high-risk groups for VAP.
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ijerph-17-00656-t001_Table 1

###### 

Occurrence of VAP in selected comorbidities.

  Comorbidities    VAP                               
  ---------------- ----- ----- ------ ------ ------- ---------
  **Diabetes**     Yes   161   9      548    29      0.016
  No               265   14    1181   48             
  **Obesity**      Yes   145   8      145    8       \<0.001
  No               281   15    1301   69             
  **Alcoholism**   Yes   68    4      133    7       \<0.001
  No               358   19    1313   70             
  **COPD**         Yes   72    4      2      \>0.5   \<0.001
  No               354   23    1444   76.5           

COPD---chronic obstructive pulmonary disease, *p*---significance level, *n*---number of patients, %---percent.

ijerph-17-00656-t002_Table 2

###### 

The occurrence of VAP vs. the cause of entering the ICU.

  Reason for Stay at the ICU          VAP                         
  ----------------------------------- ----- ---- ------ ----- --- ---------
  **Multiple organ injury**           Yes   81   4      52    3   \<0.001
  No                                  345   19   1394   74        
  **Fractures, multiple fractures**   Yes   45   2      20    1   \<0.001
  No                                  381   21   1426   76        
  **Hemorrhage, hemorrhagic shock**   Yes   10   1      137   7   \<0.001
  No                                  416   22   1309   70        

ICU---intensive care unit, *p*---significance level, *n*---number of patients, %---percent.

ijerph-17-00656-t003_Table 3

###### 

The occurrence of VAP vs. the presence of an oropharyngeal tube in intubated patients.

  Presence of Oropharyngeal Tubes   VAP Occurrence   Total   *p*                      
  --------------------------------- ---------------- ------- ------ ---- ------ ----- -------
  **Yes**                           26               1       868    24   894    25    0.003
  **No**                            360              9       2434   66   2794   75    
  **Total**                         386              10      3302   90   3688   100   

VAP---pneumonia associated with mechanical ventilation, *p*---significance level, *n*---number of patients, %---percent.

ijerph-17-00656-t004_Table 4

###### 

Occurrence of VAP vs. the type of airway breathing assist apparatus.

  Type of Airway Breathing Assist Instrument   Occurrence of VAP   Total   *p*                      
  -------------------------------------------- ------------------- ------- ------ ---- ------ ----- -------
  **Intubation**                               95                  6       1315   88   1410   94    0.047
  **Tracheotomy**                              1                   \>0.5   83     6    84     6     
  **Total**                                    96                  6       1398   94   1494   100   

VAP---pneumonia associated with mechanical ventilation, *p*---significance level, *n*---number of patients, %---percent.
